cmi_logo.png
[Latest] Global Pharmaceutical Waste Management Market Size/Share Worth USD 65.6 Billion by 2033 at a 7.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 23, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, May 23, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pharmaceutical Waste Management Market Size, Trends and Insights By Type...
SHMNLogo.jpg
SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024
May 22, 2024 12:57 ET | SOHM, Inc.
CHINO HILLS, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN)– a leading generic pharmaceutical and upstart biotechnology company, is proud to announce its ongoing...
PMV main logo.png
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
May 21, 2024 12:35 ET | PRISM MarketView
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
Captura de pantalla 2023-11-10 082355 big.png
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
SAB_Logo.png
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
May 20, 2024 17:45 ET | SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Q1 2024 Financial Results
enteralogo.png
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
May 15, 2024 08:00 ET | Entera Bio Ltd.
JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins,...
ADCT_4C_TM-R .png
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024 07:15 ET | ADC Therapeutics SA
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024...
VMR Logo.png
Flexible Packaging Market Surges to USD 292.08 Billion by 2031, Propelled by 4.89% CAGR - Verified Market Research®
May 07, 2024 10:15 ET | Verified Market Research
Lewes, Delaware, May 07, 2024 (GLOBE NEWSWIRE) -- The Global Flexible Packaging Market is projected to grow at a CAGR of 4.89% from 2024 to 2031, according to a new report published by Verified...
Josh Riggs - Oncocyte Corporation’s Chief Executive Officer
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
May 07, 2024 09:19 ET | PRISM MarketView
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
Madrigal logo.jpg
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
May 07, 2024 07:00 ET | Madrigal Pharmaceuticals, Inc.
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosisIn...